As of Friday close, Neoleukin Therapeutics Inc.’s (NASDAQ:NLTX) stock was up $0.03, moving up 3.60 percent to $0.75. The average number of shares traded per day over the past five days has been 803,820 shares. 5 times new highs have been achieved over the past 5 days, with a $0.1301 gain in that time frame. In the last twenty days, the average volume was 361,010, while in the previous 50 days, it was 333,474.
Since last month, NLTX stock rose 11.96%. Shares of the company fell to $0.6100 on 08/14/23, the lowest level in the past month. A 52-week high of $1.20 was reached on 07/17/23 after having rallying from a 52-week low of $0.38. Since the beginning of this year, NLTX’s stock price has risen by 47.37% or $0.2411, and marked a new high 19 times. However, the stock has declined by -37.49% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
NLTX stock investors should be aware that Neoleukin Therapeutics Inc. (NLTX) stock had its last reported insider trading activity 2 days ago on Aug 17. BAKER BROS. ADVISORS LP, the Director of the company, purchased of 166,942 shares for $0.69 on Aug 17. It resulted in a $115,617 investment by the insider. BAKER BROS. ADVISORS LP added 229,600 shares at an average price of $0.68 on Aug 16. The insider now owns 5,458,724 shares following the transaction. On Aug 15, Director BAKER BROS. ADVISORS LP bought 1,888,800 shares at $0.63 apiece. The transaction was valued at $1,191,616.
Financial Health
In the three months ended March 31, Neoleukin Therapeutics Inc.’s quick ratio stood at 17.20, while its current ratio was 17.20, showing that the company is able to pay off its debt. Based on annual data, NLTX earned $59.1 million in gross profit.
While analysts expected Neoleukin Therapeutics Inc. to report -$0.12 quarterly earnings, the actual figure was -$0.26 per share, beating the consensus estimate by -116.70%. The liabilities of Neoleukin Therapeutics Inc. were 14.43 million at the end of its most recent quarter ended March 31, and its total debt was $11.04 million. The value of shareholders’ equity is $44.02 million.
Technical Picture
This quick technical analysis looks at Neoleukin Therapeutics Inc.’s (NLTX) price momentum. With a historical volatility rate of 51.32%, the RSI 9-day stood at 71.42% on 18 August.
With respect to its five-day moving average, the current Neoleukin Therapeutics Inc. price is up by +20.98% percent or $0.1301. At present, NLTX shares trade +7.93% above its 20-day simple moving average and +12.92% percent above its 100-day simple moving average. However, the stock is currently trading approximately -5.88% below its SMA50 and +31.97% above its SMA200.
Stochastic coefficient K was 90.86% and Stochastic coefficient D was 77.23%, while ATR was 0.0444. Given the Stochastic reading of 82.41% for the 14-day period, the RSI (14) reading has been calculated as 60.49%. As of today, the MACD Oscillator reading stands at 0.0582, while the 14-day reading stands at 0.0589.
Analyst Ratings
Neoleukin Therapeutics Inc. (NLTX) has been rated Hold by analysts. According to 0 brokerage firms, NLTX is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Neoleukin Therapeutics Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $1.50, the current consensus forecast for the stock is $1.50 – $1.50. Based on these forecasts, analysts predict Neoleukin Therapeutics Inc. (NLTX) will achieve an average price target of $1.50.
